Supplements
ESCRS Clinical Trends Survey 2019 Results


Colin Kerr
Published: Thursday, November 5, 2020
This report contains the results of the 2019 ESCRS Clinical Trends Survey, conducted at the 37th ESCRS Congress in Paris, France. Delegates also had the option of taking the survey online at the ESCRS website. Questions addressed several areas of clinical practice, including general cataract surgery, astigmatism and toric IOLs, presbyopia correction, glaucoma and ocular surface disease. More than 2,100 doctors responded to 156 questions, which were developed and reviewed with the ESCRS leadership and substantiated by a data scientist. The survey results help ESCRS to better identify the educational needs of its members and the ESCRS leadership continually refers to the results of the annual surveys and the feedback they elicit. The collected data also enhances the education featured at the ESCRS Annual Congress, the ESCRS Winter Meeting and other educational channels, such as EuroTimes articles and online forums. We invite you to study the survey’s key findings and be ready to take advantage of upcoming educational events. ESCRS encourages all delegates to participate in the 2020 ESCRS Clinical Trends Survey here.
Latest Articles
Committing to a More Equitable Ophthalmology
Charity Committee enhances ESCRS’s reputation as a socially responsible society.
Virtual Community Unites Ukrainian Eye Specialists
Microlearning platform proves vital to saving eyes and lives in areas of conflict.
ESCRS Survey Shifts Industry Dial
Annual survey reveals trends and issues regarding the digital OR.
Always Measure the Epithelium!
Epithelium thickness mapping key to better refractive outcomes.
Advancing Vision Research
National Eye Institute initiatives encourage AI-based innovations and data interoperability.
Best Candidates for Phakic EDOF IOLs?
Patient profile suggests limits for phakic EDOF approach.
Knowing Iris Repair: Iris Repair with Prosthetic Devices
New devices on the market expand available options when iris tissue is insufficient.
Targeting the Kallikrein-Kinin System to Treat DME
Novel oral plasma kallikrein inhibitor shows promise in early clinical trial.
Faricimab VOYAGER Study
Real-world experience with faricimab for treatment-naïve nAMD and DME is underway.